Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
193,828,463
-
Total 13F shares
-
141,450,137
-
Share change
-
+837,259
-
Total reported value
-
$2,358,480,554
-
Put/Call ratio
-
58%
-
Price per share
-
$16.68
-
Number of holders
-
177
-
Value change
-
-$120,474,242
-
Number of buys
-
92
-
Number of sells
-
113
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q4 2021
As of 31 Dec 2021,
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) was held by
177 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
141,450,137 shares.
The largest 10 holders included
Kohlberg Kravis Roberts & Co. L.P., VIKING GLOBAL INVESTORS LP, VANGUARD GROUP INC, BlackRock Inc., PERCEPTIVE ADVISORS LLC, Aisling Capital Management LP, HHLR ADVISORS, LTD., AMERICAN INTERNATIONAL GROUP, INC., STATE STREET CORP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
178
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.